Navigation Links
deCODE genetics Announces First Quarter 2008 Financial Results

REYKJAVIK, Iceland, May 1 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended March 31, 2008. A conference call to discuss the quarter's results and recent operating highlights will be webcast live tomorrow, Friday, May 2, at 8:00am Eastern Time/12 noon GMT/1pm British Summer Time (details below).

Net loss for the quarter ending March 31, 2008 was $26.7 million, compared to $22.6 million for the first quarter 2007. Basic and diluted net loss per share was $0.44 for the first quarter 2008, versus $0.37 for the same quarter last year. At the close of the first quarter 2008, the company had approximately 61.8 million shares outstanding.

Revenue for the first quarter of this year increased to $15.0 million from $8.6 million for the first quarter 2007. The most significant factor in this increase in revenue is the continued growth in the company's genomic services business. At March 31, 2008, the company had $16.2 million in deferred revenue that will be recognized over future reporting periods.

Research and development expense was $12.7 million for the first quarter of this year, compared to $12.7 million for the same period last year. Our research and development expense in the past quarter includes costs related to the development and launch of our latest DNA-based tests for gauging individual risk of a growing number of common diseases and ongoing gene discovery work that is feeding our diagnostics pipeline and deCODEme service.

Selling, general and administrative expense for the first quarter of 2008 was $7.2 million, compared to $5.5 million for the 2007 period. The year-on- year increase in SG&A expense reflects in part the launch and build-up of our marketing efforts for our diagnostics and deCODEme businesses.

At March 31, 2008, the company had $69.5 million in cash, cash equivalents and investments, including restricted cash equivalents, compared to $94.1 million at December 31, 2007.

"Since the beginning of the year we have sharpened our strategic focus on capturing the commercial potential of our growing portfolio of DNA-based diagnostics for assessing risk of common diseases, and of our personal genome analysis service deCODEme(TM). We have what I believe are critical competitive advantages in these areas. In the first quarter, we have built out our marketing efforts to leverage these advantages, demonstrating our leadership in the breakthrough discoveries and the expertise in genetic analysis that distinguish the deCODE brand. We have also achieved positive clinical results for our heart attack and anti-platelet compounds DG051 and DG041, results which demonstrate the potential of these compounds as we pursue partnerships for later stage clinical development. I believe our progress over the past quarter demonstrates our commitment to realizing and capturing the value coming out of our capabilities in human genetics," said Kari Stefansson, CEO of deCODE.

Recent highlights include:

Product Development

-- Diagnostics: deCODE ProCa(TM). deCODE launched its fourth DNA-based

reference laboratory test, deCODE ProCa(TM), which detects single-

letter variations in the human genome (SNPs) that the company has

associated with increased risk of prostate cancer. deCODE believes the

test will be useful for better predicting risk of prostate cancer,

helping to optimize both screening and treatment. deCODE ProCa(TM)

detects a total of six previously discovered SNPs that have been

confirmed in many populations, as well as two SNPs on chromosomes X and

2 published by deCODE in February. Because of these variants, 10% of

men are at twice the risk and 1% of men are at three times the risk of

the disease in the general population.

-- Diagnostics: Breast cancer. In April, deCODE published its discovery of

the fourth set of common SNPs associated with risk of estrogen

receptor-positive (ER+) breast cancer. The latest SNPs are on

chromosome 5p12, and although these variants confer modest risk, they

are so common that they are estimated to account for approximately 11%

of breast cancers overall. With this latest discovery, the genetic

factors underpinning a very significant proportion of inherited risk of

ER+ breast cancer have now been elucidated. Common variants previously

discovered by deCODE on chromosomes 2q35 and 16q12 are together

involved in an estimated 25% of ER+ breast cancers. The analysis in the

April paper also reveals that a fourth known set of variants, located

on chromosome 10q26 and accounting for approximately 16% of breast

cancers, appear to confer risk exclusively of ER+ tumors. deCODE is

applying these variants as the basis for a DNA-based reference

laboratory risk-assessment test the company plans to launch in the

coming months. Such a test will allow for the identification of women

who may benefit from regular screening with standard as well as new,

high-resolution technologies.

-- deCODEme(TM). In the first quarter deCODE continued to fold its range

of new gene discoveries into the deCODEme(TM) personal genome analysis

service. The company is leveraging its breakthrough discoveries in the

marketing of deCODEme(TM), underscoring the advantages to subscribers

of choosing a genome analysis service that is not just a website, but

rather a portal to world-leading science and more than a decade of

experience in genotyping and data management. In the past three months,

subscribers have received updates on novel genetic factors involved in

prostate cancer, breast cancer, nicotine addiction and lung cancer,

osteoporosis, intracranial and abdominal aortic aneurysm, and human

fertility and evolution.

-- Heart attack - DG051. In January, the company announced positive

results from its Phase IIa clinical testing of DG051, deCODE's

developmental compound for the prevention of heart attack. DG051,

discovered by deCODE chemists, is designed to counter risk of heart

attack by reining in the activity of the leukotriene pathway, reducing

the production of the pro-inflammatory molecule leukotriene B4 (LTB4).

The results of the Phase IIa study confirmed that DG051 delivers

significant dose-dependent reductions in LTB4 in patients with a

history of heart attack or coronary artery disease and who were taking

a variety of concomitant medications. The pharmacokinetic and safety

profiles of the compound were favorable and similar to those seen in

previous studies in healthy volunteers. The company is actively seeking

a partner with whom to take the next steps in development of its

leukotriene program.

-- Arterial thrombosis: DG041. DG041 is deCODE's novel, first-in-class

antagonist of the EP3 receptor for prostaglandins E2, being developed

as a next-generation oral anti-platelet therapy for preventing arterial

thrombosis without increasing bleeding time. In clinical studies to

date, DG041 has been shown to dramatically inhibit platelet aggregation

as well as platelet activation mediated specifically through

vasodilator-stimulated phosphoprotein (VASP), a biomarker useful for

measuring platelet activity. These effects have been shown to be

concentration-dependent and irrespective of whether patients were

receiving concomitant therapy with aspirin. The company is now

concluding a second clinical pharmacology study of the effects of DG041

when taken with aspirin and Plavix(TM). deCODE is also working on a

once-daily formulation for DG041 and is exploring partnership

opportunities for the latter phases of development of DG041.

Target Discovery

-- Nicotine addiction and lung cancer. In April, deCODE scientists

reported a clear link between a single SNP and susceptibility to

nicotine dependence. Moreover, in part because of this impact on

smoking behavior, each copy of the risk variant of this SNP confers an

approximately 30% increase in risk of lung cancer and a 20% increase in

risk of peripheral arterial disease (PAD), a common and debilitating

constriction of the arteries to the legs. Roughly half of people of

European descent carry at least one copy of the variant, which the

deCODE team estimates to account for some 18% of lung cancers and 10%

of cases of PAD. These are also perhaps the highest-impact risk factors

yet found for either condition. deCODE plans to apply these findings in

the development of a DNA-based test which can be used to aid in

personalizing and increasing the effectiveness of smoking cessation

efforts, and of predicting risk of lung cancer and PAD.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA- based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; and deCODE ProCa(TM) for prostate cancer. deCODE is delivering on the promise of the new genetics.(SM) Visit us on the web at; on our diagnostics website at; and, for our pioneering personal genome analysis service, at

Conference Call Information

A conference call, during which deCODE President and CEO Kari Stefansson and CFO Lance Thibault will discuss first quarter financial results and recent operating highlights, will be webcast tomorrow, Friday, May 2, at 8:00am Eastern Time/12 noon GMT/1pm British Summer Time. The webcast can be accessed via the Investors section of deCODE's website,, or through A replay of the call will be available on these websites for at least one week following the call. A digitized telephone replay of the call can be accessed for the week following the call by dialing 1 800 475 6701 from the US, or +1 320 365 3844 from outside the US. The access code is 920841.

Condensed Consolidated Statements of Operations

For the three months

ended March 31,

2008 2007

In thousands,

except per share amounts


Revenue $14,978 $8,554


Cost of revenue 14,714 10,918

Research and development 12,653 12,676

Selling, general and administrative 7,211 5,530

Total operating expense 34,578 29,124

Operating loss (19,600) (20,570)

Interest income 1,037 1,991

Interest expense (4,025) (3,666)

Other non-operating income and (expense), net* (4,077) (380)

Net loss $(26,665) $(22,625)

Basic and diluted net loss per share: $(0.44) $(0.37)

Shares used in computing basic and

diluted net loss per share 61,266 60,949

Condensed Consolidated Balance Sheet Data

At March 31, At December 31,

2008 2007

In thousands,


Cash and investments ** $69,490 $94,058

Total assets 134,055 156,208

Total liabilities 303,520 301,858

Total shareholders' equity (deficit) (169,465) (145,650)

* Other non-operating expense for the three months ended March 31, 2008

principally reflects an unrealized loss resulting from the revaluation

of the company's non-current auction rate securities investments as of

March 31, 2008.

** Cash and investments include cash equivalents, restricted cash

equivalents and current and non-current investments.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


deCODE genetics

Joy Bessenger Gisli Arnason

+354 570 1900 +354 570 1825

+1 (212) 481 3891

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
2. deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information
3. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
4. U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
5. A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease
6. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
7. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
8. deCODE Genetics Announces Full-year 2007 Financial Results
9. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
10. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
11. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
Post Your Comments:
(Date:10/13/2015)... ALBANY, New York , October 13, 2015 ... Share, Growth, Trends, and Forecast 2015 - 2023 " ... bn in 2014 and is anticipated to reach US$7.59 bn by ... from 2015 to 2023. --> " Microbiology Culture ... 2015 - 2023 " , the global microbiology ...
(Date:10/13/2015)... TapImmune, Inc. (TPIV), a ... peptide and gene-based immunotherapeutics and vaccines for the treatment ... presenting company at the Dawson James Small Cap ... Jupiter, Florida on October 15, ... clinical-stage immunotherapy company specializing in the development of innovative ...
(Date:10/13/2015)... Charlotte, NC (PRWEB) , ... October 13, 2015 ... ... high intensity focused ultrasound (HIFU) technologies, announced today that it received de novo ... 450 in the U.S. for the ablation of prostate tissue. Sonablate® is ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... Spirax Sarco, ... the release of the CSM-C 600 compact clean steam generator . This ... that meets the requirements of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 ...
Breaking Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
Breaking Biology News(10 mins):